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sirtuins in metabolism, aging and diseaseMichele M. Maxwell1, Julien Francisco Zaldivar-Jolissaint2, Antonello Mai3,
Tiago F. Outeiro4, Aleksey G. Kazanstev1*From February 12–16, 2012, leading members of the sirtuin scientific community assembled in Tahoe, CA to attend the Keystone
Symposium ‘‘Sirtuins in Aging, Metabolism, and Disease.’’ It was a vibrant and livelymeeting, and in the spirit of Keystone Symposia,
both established sirtuin researchers and those new to the field enjoyed a unique opportunity to interact and exchange ideas.Aleksey Kazantsev opened the Sympo-
sium by highlighting the explosion of
research on sirtuins, the evolutionarily
conserved NADþ(nicotinamide adenine
dinucleotide)-dependent protein deace-
tylases that are homologues of the yeast
longevity gene Sir2. In the Keynote
Address, Leonard Guarente provided
an overview of the sirtuin deacetylases,
which act on a wide variety of protein
targets including histones, transcription
factors and apoptotic modulators. More-
over, some sirtuins possess other enzy-
matic activities, such as the mono-ADP-
ribosyl transferase activity attributed
to mammalian SIRT4. Dr. Guarente
described the sirtuins as key sensors for
available energy stores that function as a
link between protein acetylation and
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the terms of the Creative Commons Attribution-NonCom
reproduction in any medium, provided the original workdebate over the role of sirtuins in the
positive responses to calorie restriction
(CR), he emphasized that most available
data in yeast and invertebrates strongly
suggest that the beneficial effects of CR
require sirtuin activity and stressed the
importance of extending these findings to
mammals. Dr. Guarente also discussed
evidence from current studies demon-
strating that (i) sirtuins appear to sup-
press diseases of aging; (ii) sirtuin
activity declines with aging; and
(iii) sirtuins are novel therapeutic targets
for many age-related diseases. More
specifically, he showed compelling evi-
dence that mammalian SIRT1 activity
protects against age-associated patholo-
gies such as diabetes and obesity.Sirtuins in metabolism
The emerging roles of sirtuins, particu-
larly mammalian SIRT1, in regulating
both cellular and organismal metabolism
were emphasized throughout the meet-
ing. John Denu discussed the role of
SIRT1 as a major regulator of central
cellular metabolic pathways, focusing on
new protein targets of this enzyme. He
showed that SIRT1 deacetylates and
thereby downregulates activity of phos-
phoglycerate mutase 1 (PGAM1), an
enzyme not thought to be regulated in
the glycolytic pathway but now known to
catalyse a rate-limiting step of glycolysis, Ltd on behalf of EMBO. This is an open access article un
mercial License, which permits use, distribution and
is properly cited.in cancer cells. This raises the possibility
that reduced activity of SIRT1 in high-
glucose conditions results in hyperacety-
lated PGAM1, which increases energy
production via the glycolytic pathway.
Intriguing insights have been gleaned
from new mouse models – developed to
circumvent the embryonic lethality of
SIRT1 knockout (KO) mice – that either
lack or overexpress SIRT1 in a tissue-
specific and/or inducible manner. Vit-
torio Sartorelli described a tamoxifen-
inducible muscle-specific SIRT1 KO
mouse. On a high-fat diet (HFD), these
KOmice gainmoreweight than their wild-
type (WT) counterparts and exhibit
decreased peripheral insulin sensitivity
and increased fatty acid (FA) accumula-
tion. KOmice also showmarked reduction
in the expression of enzymes involved in
oxidative phosphorylation. This study
suggests that muscle SIRT1 is important
for adaptation to HFD and that its loss is
sufficient to induce a pathologic response.
David Sinclair described studies in
tamoxifen-inducible whole body SIRT1
KO mice: WT and KO mice were fed
either a standard diet (SD) or a HFD, with
or without supplementation with the
natural polyphenol compound resvera-
trol. SIRT1 KO mice showed decreased
mitochondrial function on SD, similar to
WTmice onHFD.Mitochondrial function
improved in WT, but not KO, mice in
response to low-dose resveratrol treat-
ment, suggesting that these effects areder
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558SIRT1-dependent; however, treatment
with high-dose resveratrol showed
SIRT1-independent effects, presumably
due to the compound acting on other
targets.
Rafael de Cabo further illuminated the
role of SIRT1 in regulating metabolism
and promoting healthy aging, describing
longitudinal studies in mice and primates
treated with resveratrol and other SIRT1-
activating compounds (STACs). In mice,
resveratrol treatment of HFD-fed animals
normalized both survival and overall
metabolic indicators to those observed
in animals fed SD without resveratrol.
Dr. de Cabo emphasized that, although
resveratrol likely acts via multiple targets
to exert broad effects, significant benefits
of this compound have been observed in
many models. Further, the novel STAC
SRT1720 also exerts positive effects in
HFD-challenged mice: treated animals
exhibited a slight decrease in body
weight, improved insulin sensitivity,
and decreased incidence of cataracts.Sirtuins in cardiovascular
disease
Other speakers highlighted the role of
SIRT1 and microRNAs in age-dependent
cardiovascular disease (CVD). Stefanie
Dimmeler pointed out that age is the
biggest risk factor for CVD in humans and
is associated with increased cardiac
fibrosis, apoptosis, heart failure, and
decreased neovascularization after ische-
mia. Several microRNAs have been
shown to be regulated by aging; notably,
a subset of these microRNAs also control
SIRT1 expression and cardiovascular
functions. In line with these observa-
tions, Lindsey Gano showed that age-
related vascular endothelial dysfunction,
an indicated by impaired endothelium-
dependent dilation (EDD), was amelio-
rated in aged mice treated with the STAC
SRT1720. Improvement in EDD was
accompanied by restoration of aortic
SIRT1 activity in treated animals.SIRT1-activating compounds
Several presentations directly addressed
the ongoing debate over the mechan- 2012 The Authors. Published by John Wiley and Sonsism(s) of action of resveratrol and other
STACs. David Sinclair and George
Vlasuk both showed data demonstrating
that a specific amino acid residue, E230,
which lies in a structured amino-terminal
region of SIRT1, is required for activation
via resveratrol and other STACs
developed by Sirtris/GSK. These results
suggest that STACs that fail to activate
E230 mutants are direct activators of
SIRT1.
However, Jay Chung questioned
whether STACs such as resveratrol
directly activate SIRT1 in vivo, or
whether these compounds in fact act
on upstream molecules that subse-
quently activate SIRT1. In Dr. Chung’s
studies, both resveratrol and SRT1720
were robust AMPK activators and inhib-
ited cAMP phosphodiesterases (PDEs).
He suggested that the predominant effect
of resveratrol is PDE inhibition and
downstream AMPK activation. Others
disagreed with that interpretation,
arguing that some STAC compounds lack
PDE binding. Moreover, Clemens Steeg-
born showed data indicating that mod-
ulation of SIRT1 by resveratrol is sub-
strate-specific and that this effect might
be due to compound interaction with
both the enzyme and its substrate. There
was general agreement among partici-
pants that the extent to which STACs
act directly on sirtuins will be critical
to the development of these molecules
for therapeutic application in human
patients.Mitochondrial and other sirtuins
Several talks focused on the roles of the
mitochondrial sirtuins, particularly
SIRT3, in regulating cellular metabolism.
Eric Verdin showed that mitochondrial
proteins from SIRT3 KO mice are hyper-
acetylated, suggesting that SIRT3 is the
major mitochondrial protein deacetylase.
SIRT3 is induced during fasting and
downregulated in animals fed HFD. The
Verdin lab has generated new Cre-
dependent SIRT3-overexpressing trans-
genic mouse lines that will be used to
determine whether overexpression of
SIRT3 increases insulin sensitivity and
FA oxidation and decreases reactive
oxygen species (ROS) production., Ltd on behalf of EMBO.Further, a proteomics approach identified
many proteins involved in FA oxidation
and amino acid metabolism as potential
SIRT3 targets. In accordance with these
results, Marcia Haigis reported metabo-
lomics studies showing that loss of SIRT3
upregulates glycolysis via stabilization of
HIF-1a. Dr. Haigis suggested that stabi-
lization of HIF-1a even in high oxygen
conditions could account in part for the
‘‘Warburg Effect’’ observed in cancer
cells. Finally, Andrew Dillin provided
compelling evidence that cells in multi-
cellular organisms might orchestrate
their responses to energetic challenge
via humoral control of mitochondrial
form and function.
New insights were gained regarding
the activities of some of the less well-
understood sirtuins. Eric Verdin
described a novel activity for SIRT5 as
a protein demalonylase as well as a
desuccinylase. Hening Lin also showed
that SIRT5 is an efficient desuccinylase/
demalonylase and that other sirtuins
that are weak deacetylases have novel
activities as well.Sirtuins in metabolism and
cancer
Several speakers described emerging
findings linking the chromatin-associated
sirtuin SIRT6 to metabolism and cancer.
John Dominy showed that PGC-1a, a
well-known deacetylation target of
SIRT1, is hyperacetylated upon over-
expression of SIRT6. Haim Cohen
described results from SIRT6-overexpres-
sing mice, which were previously shown
to be resistant to the negative effects of
HFD. Increased SIRT6 expression extends
lifespan in male but not female mice; as a
result, SIRT6-overexpressing males now
live as long as females. Extension of
lifespan in males on HFD is associated
with improved glucose homeostasis and
decreased serum IGF1, such that levels in
males become comparable to that
observed in females. Dr. Cohen pointed
out that this ‘‘feminization’’ of gene
expression patterns is also observed in
males after CR.
Katrin Chua and Raul Mostoslasky
both described findings in SIRT6 KO
mice, which show genomic instabilityEMBO Mol Med (2012) 4, 557–560
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damage as well as acute degenerative and
metabolic pathology; these animals die at
4 weeks of age due to hypoglycemic
crash. Dr. Chua reported that the early
lethality of SIRT6 KO mice can be over-
come by a temporary dietary regimen
rich in fat and glucose; this approach
revealed later-life phenotypes of SIRT6-
deficiency, including some intriguing
behavioural abnormalities. Dr. Chua
described her findings that SIRT6 is a
histone H3K9 and H3K56 deacetylase
that regulates telomeric chromatin and
NF-kB-dependent gene expression and
then presented new evidence that SIRT6
is important for mitotic fidelity. SIRT6
deficiency leads to mitotic errors and
aneuploidy, and SIRT6 KO MEFs show
accelerated spontaneous immortaliza-
tion, a hallmark of cancer cells.
Dr. Mostoslavsky showed an increase
in glucose uptake in brown adipose tissue
(BAT) and muscle in SIRT6 KOmice, and
suggested that this increased glucose
uptake is responsible for the acute
hypoglycemia. SIRT6 KO mice also
exhibit increased lactate production and
inhibition of mitochondrial respiration,
resembling the Warburg Effect in tumour
cells. ChIP experiments revealed associa-
tion of SIRT6 with key genes involved in
glycolysis, and SIRT6 effects are
mediated by deacetylation of H3K9,
which is hyperacetylated in the SIRT6
KO mouse and is associated with
increased binding of HIF-1a and activa-
tion of glycolytic gene expression.
Whether SIRT6 may act as a tumour
suppressor by modulating the Warburg
Effect remains to be established.
In another link between sirtuins,
metabolism and cancer, SIRT3 KO mice
develop tumours at 1 year of age.Marcia
Haigis showed that analysis of human
tumours showed SIRT3 LOH in 40% of
breast and ovarian tumours and reduced
SIRT3 expression (<50%) in 85% of
patients. Finally, Katrin Chua described
a novel activity for SIRT7 in tumourigen-
esis, showing that this sirtuin selectively
deacetylates H3K18 to stabilize the
transformed state of cancer cells.
In contrast to the proposed anti-
tumourigenic roles proposed for SIRT3,
SIRT6, and SIRT7, Lucia Altucci and
Alejandro Vaquero both discussed theEMBO Mol Med (2012) 4, 557–560therapeutic potential of specific sirtuin
inhibitors as anti-cancer agents.
Dr. Altucci showed that a dual SIRT1/
SIRT2 inhibitor increased caspase activa-
tion and cell death in cultured leukaemia
cells and induced apoptosis in both
tumour cell lines and in cells from
primary tumours. The SIRT1/2 inhibitor
also exerted anti-tumourigenic effects in
allograft and xenograft models in vivo.
Dr. Vaquero showed that cells from
SIRT2 KO mice exhibit increased prolif-
eration, DNA damage, and genomic
instability. These changes were asso-
ciated with hyperacetylation of H4K16.
Intriguingly Mario Fraga observed
decreased SIRT1 RNA and protein levels
during human ES cell differentiation and
a concomitant increase in acetylation of
the putative SIRT1 target H4K16.Sirtuin modulators
There was a strong focus throughout the
meeting on discovery of sirtuin modula-
tors, underscoring the widespread inter-
est in developing sirtuin-based drugs.
Clemens Steegborn used acetylome
peptide microarrays to identify distinct
substrate specificities for mammalian
sirtuins, suggesting limited direct com-
pensation of sirtuin paralogs. He also
described differential inhibition of mam-
malian sirtuins by nicotinamide, a dea-
cetylation by-product, and different
potencies against Sirt5-dependent turn-
over of acetylated or succinylated sub-
strates. Antti Poso used virtual docking
approaches to model sirtuin–substrate
interactions and described structural
features of this interaction that compli-
cate development of novel sirtuin mod-
ulators. Manfred Jung and Antonello
Mai both described targeted approaches
for developing sirtuin inhibitors. Because
kinase inhibitors are ATP mimics that
might also interact with NADþ-binding
sites, Dr. Jung screened a focused library
of kinase inhibitors to identify sirtuin
inhibitors and identified a PKC inhibitor
with an IC50 value of 800 nM for SIRT2.
Dr. Mai detailed a medicinal chemistry
approach for developing new classes of
sirtuin modulators and evaluating their
antiproliferative activities. The best
effects were achieved with a dual 2012 The Authors. PublishSIRT1/SIRT2 inhibitor, and both activ-
ities appear to be required for anti-
proliferative activity. Dr. Mai noted that
some 1,4-dihydropyridine compounds
with sirtuin activating properties also
show antiproliferative effects. Yana Cen
described the use of kinetic isotope
effects (KIEs) to study biochemical tran-
sition states of sirtuins from Plasmodium
and Archaeoglobus, which might aid in
designing novel sirtuin inhibitors.Sirtuins in metabolism, aging
and neuronal function
Finally, several presentations suggested a
key role for sirtuins in linking metabo-
lism, aging and neuronal function.
Describing the ‘NADWorld’ as a systemic
regulatory network connecting metabo-
lism and aging, Shin-ichiro Imai pre-
sented new results from detailed analyses
of brain-specific SIRT1-overexpressing
(BRASTO) mice, including effects on
longevity and age-associated physiologi-
cal changes. Dr. Imai also suggested a
molecular mechanism by which SIRT1
regulates hypothalamic neural activities
that affect the aging process and possibly
longevity. This presentation stimulated
discussions on the importance of sirtuins
for the control of aging and longevity in
mammals.
Sergiy Libert described two new
mouse models in which SIRT1 is either
specifically deleted (BSKO) or overex-
pressed (OX) in brain. BSKO mice exhibit
increased exploratory behaviour, while
OX mice explore less. Behaviour in OX
mice is normalized by SSRI antidepres-
sants, suggesting that OX mice have
impaired serotonin signalling. In the
forced swim test, BKSO mice are less
passive and OX mice are more passive;
BSKO mice also have increased levels of
serotonin, noradrenalin and 5HAA, and
all of these are reduced in OX animals.
Several speakers described efforts to
probe the role of sirtuins in neurons and
to investigate the therapeutic potential of
sirtuin modulators for treating neurolo-
gical diseases, especially age-dependent
neurodegenerative disorders. Larry
Marsh used a Drosophila model of
Huntington’s disease (HD) to screen for
modifiers of polyglutamine-induced neu-ed by John Wiley and Sons, Ltd on behalf of EMBO. 559
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560rotoxicity and identified sir2 (Drosophila
homolog of SIRT1) and sirt2. The
observed beneficial effects were strik-
ingly dependent on gene dosage: hetero-
zygotes showed improved phenotype but
homozygous deletion increased neuro-
degeneration. Treatment with selistat, a
specific sir2 inhibitor, provided dose-
dependent neuroprotection but this effect
again required some sir2 to be present.
Resveratrol was also protective in the fly
model but its effects do not appear to
require sir2, since they were also
observed in sir2/ animals. In contrast
to the beneficial effects of inhibiting sir2
in the fly, Christian Neri showed that in
Caenorhabditis elegans, overexpression
of sir2.1 (worm SIRT1) protects against 2012 The Authors. Published by John Wiley and Sonspolyglutamine-induced neuronal dysfunc-
tion while both sir2.1 loss-of-function and
sir-2.1 RNAi exacerbate the phenotype. In
a mouse model of HD, Wenzhen Duan
showed that SIRT1 overexpression is
neuroprotective and ameliorates beha-
vioural deficits, perhaps by increasing
expression of important neurotrophins
such as BDNF. Lastly, Ruth Luthi-Carter
described a potential mechanism for the
benefits of SIRT2 inhibition in a primary
striatal neuron model of Huntington’s
disease. Together, these studies high-
lighted key questions surrounding efforts
to develop sirtuin modulators for treat-
ment of neurological diseases, including
whether it is activation or inhibition of
specific sirtuins that is beneficial., Ltd on behalf of EMBO.Concluding remarks
In his closing remarks, Rafael de
Cabo emphasized the importance of
studying healthy aging, i.e. healthspan,
in addition to lifespan, arguing that aging
is the major risk factor for all human
disease and that the goal of aging
research is to achieve not more years,
but more healthy years. Overall, the
results presented at this meeting support
the development of sirtuin-based thera-
pies as a promising therapeutic approach
for treatment of age-related human
diseases.
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